What question did this study set out to answer?

To evaluate the efficacy and safety evidence for combining biologic agents with phototherapy in patients with moderate-to-severe plaque psoriasis.

July 1, 2016Psoriasis Targets and TherapyOpen Access

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability

View Full Paper

Ask AI

Bookmark

Authors

BFBenjamin Farahnik VPViraat Patel KBKourosh Beroukhim

Discussion

Member takes

Overview

Literature review reveals enhanced clearance and low severe adverse events in moderate-to-severe psoriasis, suggesting combination biologic and phototherapy is an effective clinical strategy.

Key Points

To evaluate the efficacy and safety evidence for combining biologic agents with phototherapy in patients with moderate-to-severe plaque psoriasis.
Searched PubMed through January 2016 for English-language studies evaluating combination biologic and phototherapy regimens in moderate-to-severe psoriasis.
Identified primary literature encompassing randomized controlled trials, a head-to-head trial, open-label trials, case series, and case reports analyzing agents such as etanercept, adalimumab, infliximab, and ustekinumab.
Etanercept was the biologic evaluated in over 50% of reported cases, and narrowband ultraviolet B (NBUVB) radiation was the predominant phototherapy modality.
Most reviewed cases demonstrated enhanced clinical clearance when combining biologics with phototherapy relative to monotherapy.
Serious adverse events occurred in <3% of patients during study periods, though potential long-term adverse events remain uncharacterized.

Cite This Study

Farahnik et al. (2016) studied this question.

synapsesocial.com/papers/6a70f439f44fa9f079deb5cf https://doi.org/10.2147/ptt.s98952

View Full Paper

Ask AI

Bookmark

July 1, 2016Psoriasis Targets and TherapyOpen Access

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability

View Full Paper

Ask AI

Bookmark

Authors

BFBenjamin Farahnik VPViraat Patel KBKourosh Beroukhim

Discussion

Member takes

Overview

Literature review reveals enhanced clearance and low severe adverse events in moderate-to-severe psoriasis, suggesting combination biologic and phototherapy is an effective clinical strategy.

Key Points

To evaluate the efficacy and safety evidence for combining biologic agents with phototherapy in patients with moderate-to-severe plaque psoriasis.
Searched PubMed through January 2016 for English-language studies evaluating combination biologic and phototherapy regimens in moderate-to-severe psoriasis.
Identified primary literature encompassing randomized controlled trials, a head-to-head trial, open-label trials, case series, and case reports analyzing agents such as etanercept, adalimumab, infliximab, and ustekinumab.
Etanercept was the biologic evaluated in over 50% of reported cases, and narrowband ultraviolet B (NBUVB) radiation was the predominant phototherapy modality.
Most reviewed cases demonstrated enhanced clinical clearance when combining biologics with phototherapy relative to monotherapy.
Serious adverse events occurred in <3% of patients during study periods, though potential long-term adverse events remain uncharacterized.

Cite This Study

Farahnik et al. (2016) studied this question.

synapsesocial.com/papers/6a70f439f44fa9f079deb5cf https://doi.org/10.2147/ptt.s98952

View Full Paper

Ask AI

Bookmark